Related Experiment Video
Updated: Oct 12, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
French vascular physicians' practices in indicating antiplatelet and anticoagulation therapy in venous
Antoine Fayol1, Damien Lanéelle2, Clément Hoffmann3
11 Service de Médecine Interne, Hôpital Louis Mourier (Colombes), Assistance Publique - Hôpitaux de Paris (APHP), Université Paris 7, Paris, France.
Insights
French vascular physicians acknowledge increased bleeding risk when combining antiplatelet agents (APA) and anticoagulants for venous thromboembolism (VTE). Management strategies varied significantly among physicians, highlighting the need for comparative trials.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Clinical Pharmacy
Background:
- Widespread antiplatelet therapy (APA) use presents challenges in managing patients requiring anticoagulation for venous thromboembolism (VTE).
- Combining APA and anticoagulants increases bleeding risk by 1.5-2.5 fold.
- Current management strategies for this dual therapy in VTE patients are not standardized.
Purpose of the Study:
- To evaluate the management practices of French vascular physicians regarding the combined use of APA and anticoagulants in VTE patients.
- To assess physician approaches at both the initiation of treatment and at the 6-month follow-up point.
Main Methods:
- A survey was conducted among French vascular physicians between September and December 2017.
- The survey utilized fictional scenarios and isolated questions presented via an online questionnaire.
- 179 valid responses were collected from 1812 physicians, yielding a 9.9% response rate.
Main Results:
- 97.2% of physicians recognized the elevated bleeding risk associated with combined APA and anticoagulant therapy.
- 63% of respondents discontinued APA upon initiating anticoagulation, while 36% did not.
- Four distinct management strategies were identified, with variations in anticoagulant dosage and APA continuation at 6 months.
Conclusions:
- French vascular physicians employ diverse treatment strategies based on perceived risk-benefit ratios.
- Significant heterogeneity exists in clinical practice for managing VTE patients on dual antiplatelet and anticoagulant therapy.
- Further randomized controlled trials are necessary to establish evidence-based recommendations for optimal management.
Abstract:
Background: As antiplatelet therapy becomes widespread, physicians face the issue patients being treated with antiplatelet agents (APA) and anticoagulants for venous thromboembolism (VTE). Bleeding risk of this combination is increased 1.5-2.5-fold. The aim of this survey is to assess French vascular physician's management of this combination at the beginning of the treatment and at 6 months of treatment for VTE. Patients and methods: French vascular physicians were surveyed between September and December 2017, using 4 fictional scenarios regarding a VTE event diagnosed in a patient under antiplatelet therapy plus isolated questions in an online questionnaire, sent by the French Society of Vascular Medicine to its members. Out of 1812 physicians, 179 returned valid questionnaires: the response rate was 9.9%. Results: Firstly 97.2% of respondents acknowledged extra risk with this combination; and 63% ceased antiplatelet therapy when initiating anticoagulants; while 36% did not. Secondly, four strategies emerged: 31.4% ceased APA and prescribed full-dose anticoagulants at initiation and at 6 months; 32% associated reduced-dose anticoagulation with APA at 6 months, regardless of what they decided at initiation; 16.5% prescribed isolated full-dose anticoagulants at initiation and reduced-dose at 6 months; lastly 11.2% associated full-dose anticoagulant with antiplatelet therapy at initiation and at 6 months. Conclusions: French vascular physicians adopted different strategies according to estimated risk/benefit ratio. Prospective randomized controlled trials should compare these strategies in order to make recommendations.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

